非酒精性脂肪性肝病营养干预研究进展*

doi:10.3969/j.issn.1672-5069.2024.01.039

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是世界范围内最常见的肝病。由于缺乏有效的针对性治疗药物,通过饮食干预降低体质量和改善代谢是处理NAFLD患者最基本的方法。本文总结了NAFLD相关饮食干预的研究进展,并探讨了作用机制和治疗作用,以便更好地指导临床实践。

关键词: 非酒精性脂肪性肝病, 营养干预, 饮食

Abstract: The nonalcoholic fatty liver disease (NAFLD) is the most common liver diseases worldwide. Currently, due to the lack of effective drugs for treatment of NAFLD, the scholars recommend reducing body weight and improving metabolism through dietary interventions. In this paper, we summarize the research progress of NAFLD-related dietary interventions and the mechanisms by which they play roles in therapeutic effects in order to better guide clinical practice.

Key words: Nonalcoholic fatty liver diseases, Nutritional intervention, Dietary strategies

蔺宁, 孔明, 段钟平. 非酒精性脂肪性肝病营养干预研究进展^*[J]. 实用肝脏病杂志, 2024, 27(1): 151-154.

Lin Ning, Kong Ming, Duan Zhongping. Nutritional intervention for patients with non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2024, 27(1): 151-154.

参考文献

[1] Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence,incidence,and outcomes.Hepatology,2016,64(1):73-84.
[2] 张薇,魏来.非酒精性脂肪性肝病在亚洲的流行情况.中华肝脏病杂志,2013,21(11):801-804.
[3] 中国研究型医院学会肝病专业委员会,中国医师协会脂肪性肝病专家委员会,中华医学会肝病学分会脂肪肝与酒精性肝病学组,等.中国脂肪性肝病诊疗规范化的专家建议(2019 年修订版).中华肝脏病杂志, 2019, 27(10): 748-753.
[4] Wattacheril J.Extrahepatic manifestations of nonalcoholic fatty liver disease.Gastroenterol Clin North Am,2020,49(1):141-149.
[5] Eslam M,Newsome PN,Sarin SK,et al.A new definition for metabolic dysfunction-associated fatty liver disease:An international expert consensus statement.J Hepatol,2020,73(1): 202-209.
[6] Nan Y,An J,Bao J,et al.The Chinese society of hepatology position statement on the redefinition of fatty liver disease.J Hepatol,2021,75(2): 454-461.
[7] Younossi ZM,Corey KE, Im JK.AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review.Gastroenterology,2021,160(3): 912-918.
[8] European association for the study of the liver (EASL),European association for the study of diabetes (EASD),European association for the study of obesity (EASO).EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease.J Hepatol,2016, 64(6): 1388-1402.
[9] Eslam M, Sarin SK, Wong VW,et al.The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int,2020, 14(6): 889-919.
[10] Lu FB,Zheng KI,Rios RS,et al.Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol,2020, 35(12): 2041-2050.
[11] Tsompanaki E,Thanapirom K,Papatheodoridi M,et al.Systematic review and meta-analysis: The role of diet in the development of nonalcoholic fatty liver disease.Clin Gastroenterol Hepatol,2023,21(6):1462-1474.
[12] Kirk E, Reeds DN, Finck BN, et al. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology, 2009, 136(5): 1552-1560.
[13] Browning JD, Baker JA, Rogers T, et al. Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr, 2011, 93(5): 1048-1052.
[14] Johansson HE, Edholm D, Kullberg J, et al. Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements. Nutr Diabetes, 2019, 9(1): 34.
[15] Ma J, Hennein R, Liu C,et al. Improved diet quality associates with reduction in liver fat, particularly in individuals with high genetic risk scores for nonalcoholic fatty liver disease. Gastroenterology, 2018, 155(1): 107-117.
[16] Ryan MC, Itsiopoulos C, Thodis T,et al. The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease. J Hepatol, 2013, 59(1): 138-143.
[17] Properzi C, O'Sullivan TA, Sherriff JL,et al. Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial. Hepatology, 2018, 68(5): 1741-1754.
[18] Ryan MC, Abbasi F, Lamendola C,et al. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care, 2007, 30(5): 1075-1080.
[19] Donnelly KL, Smith CI, Schwarzenberg SJ,et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 2005, 115(5): 1343-1351.
[20] Mozaffarian D, Hao T, Rimm EB,et al. Changes in diet and lifestyle and long-term weight gain in women and men. N Engl J Med, 2011, 364(25): 2392-2404.
[21] Summary for patients: Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease. Ann Intern Med, 2023, 176(1): I18.
[22] Parker A, Kim Y. The effect of low glycemic index and glycemic load diets on hepatic fat mass, insulin resistance, and blood lipid panels in individuals with nonalcoholic fatty liver disease. Metab Syndr Relat Disord, 2019, 17(8): 389-396.
[23] Tendler D, Lin S, Yancy WS Jr, et al. The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci, 2007, 52(2): 589-593.
[24] Luukkonen PK, Dufour S, Lyu K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A. 2020, 117(13): 7347-7354.
[25] Rinaldi R, De Nucci S, Castellana F, et al.The effects of eight weeks' very low-calorie ketogenic diet (VLCKD) on liver health in subjects affected by overweight and obesity. Nutrients,2023, 15(4): 825.
[26] Cunha GM, Guzman G, Correa De Mello LL, et al. Efficacy of a 2-month very low-calorie ketogenic diet (VLCKD) compared to a standard low-calorie diet in reducing visceral and liver fat accumulation in patients with obesity. Front Endocrinol (Lausanne), 2020, 11: 607.
[27] Phillips SM, Chevalier S, Leidy HJ. Protein "requirements" beyond the RDA: implications for optimizing health. Appl Physiol Nutr Metab,2016, 41(5): 565-572.
[28] Campisano SE, Echarte SM, Podaza E, et al. Protein malnutrition during fetal programming induces fatty liver in adult male offspring rats. J Physiol Biochem, 2017, 73(2): 275-285.
[29] Bortolotti M, Kreis R, Debard C,et al. High protein intake reduces intrahepatocellular lipid deposition in humans. Am J Clin Nutr,2009, 90(4): 1002-1010.
[30] Markova M, Pivovarova O, Hornemann S, et al. Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes. Gastroenterology, 2017, 152(3): 571-585.
[31] Torres-Peña JD, Arenas-de Larriva AP, Alcala-Diaz JF, et al. Different dietary approaches, non-alcoholic fatty liver disease and cardiovascular disease: a literature review. Nutrients, 2023, 15(6): 1483.
[32] Zeng X, Xie S, Jiang F,et al. Association between time-restricted eating and nonalcoholic fatty liver disease in a nationwide cross-sectional study. Br J Nutr, 2023, 27: 1-8.
[33] Wei X, Lin B, Huang Y, et al. Effects of time-restricted eating on nonalcoholic fatty liver disease: The TREATY-FLD randomized clinical trial.JAMA Netw Open,2023,6(3): e233513.
[34] Johari MI,Yusoff K,Haron J,et al.A randomised controlled trial on the effectiveness and adherence of modified alternate-day calorie restriction in improving activity of non-alcoholic fatty liver disease.Sci Rep,2019,9(1):11232.
[35] Holmer M,Lindqvist C,Petersson S,et al.Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet - a randomised controlled trial.JHEP Rep,2021,3(3):100256.

非酒精性脂肪性肝病营养干预研究进展^*

Nutritional intervention for patients with non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄洁杰, 郑倩, 吕睿, 王瑞萍. 利拉鲁肽联合阿托伐他汀钙治疗伴有糖脂代谢异常的非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 36-39.
[2]	王文川, 梁阔鹏, 何蕊玲, 王继涛, 吉晓林, 刘成禹, 张宣哲, 张清格, 郭海军, 张健, 高华方, 郑少阳, 祁小龙, 刘登湘. 社区2型糖尿病合并NAFLD患病流行率调查^*[J]. 实用肝脏病杂志, 2024, 27(1): 40-43.
[3]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[4]	周季颖, 谢月红, 于翠霞. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 793-796.
[5]	卢蓉, 李慧, 张超, 邵正健, 罗大光. 甘油三酯/葡萄糖指数预测非酒精性脂肪性肝病严重程度效能研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 805-810.
[6]	邵孝如, 周筱, 葛颖颖. ¹⁸F-FDG摄取量诊断非酒精性脂肪性肝病患者罹患冠状动脉粥样硬化性心脏病探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 811-814.
[7]	丁晓洁, 张永明, 宋海燕, 王文平, 宋洁, 撒小军, 邹永红. 2型糖尿病合并非酒精性脂肪性肝病患者NLR和PLR变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(6): 815-818.
[8]	侯义林, 曹风华, 纪小燕, 蔡燕. 非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 819-822.
[9]	王卓雅, 吴洋鹏, 黄益桃. 还原型谷胱甘肽联合护肝清脂片治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(6): 823-826.
[10]	韩仕杉, 赵彩彦. Betatrophin与非酒精性脂肪性肝病[J]. 实用肝脏病杂志, 2023, 26(6): 930-933.
[11]	吴非, 郭雯, 张群. 非酒精性脂肪性肝病患者骨骼肌质量变化研究^*[J]. 实用肝脏病杂志, 2023, 26(5): 646-649.
[12]	黄龙, 范雅茜, 段钟平. 舒肝宁注射液利胆退黄抗炎护肝机制研究进展^*[J]. 实用肝脏病杂志, 2023, 26(5): 765-768.
[13]	顾棨, 芮法娟, 倪文婧, 陈倩倩, 吴超, 施军平, 李婕. 非酒精性脂肪性肝病的规范化管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 457-459.
[14]	何方平. 我国NAFLD慢病管理实践现状和建议[J]. 实用肝脏病杂志, 2023, 26(4): 460-462.
[15]	王卓雅, 吴洋鹏, 黄益桃. 多烯磷脂酰胆碱联合脂必泰治疗非酒精性脂肪性肝病患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 496-499.